Safety of COVID-19 Vaccination in Those with MS, NMOSD, and MOGAD
A recent paper outlined the findings of a new study on the safety and efficacy of COVID-19 vaccines in patients with Multiple Sclerosis (MS), Neuromyelitis Optica spectrum disorder (NMOSD), and Myelin Oligodendrocyte Glycoprotein antibody disease (MOGAD). Researchers in South Korea examined the medical records of 56 patients (19 with MS, 22 with NMOSD, and 15 with MOGAD) to determine the effects of vaccination on this population.
Read More »